Five-year Clinical and Economic Outcomes Among Patients With Medically Managed Severe Aortic Stenosis: Results From a Medicare Claims Analysis

M. A. Clark, S. V. Arnold, F. G. Duhay, A. K. Thompson, M. J. Keyes, L. G. Svensson, R. O. Bonow, B. T. Stockwell, D. J. Cohen
2012 Circulation. Cardiovascular Quality and Outcomes  
The online-only Data Supplement is available at http://circoutcomes.ahajournals.org/lookup/suppl/Background-Patients with severe, symptomatic aortic stenosis, who do not undergo valve replacement surgery have a poor long-term prognosis. Limited data exist on the medical resource utilization and costs during the final stages of the disease. Methods and Results-We used data from the 2003 Medicare 5% standard analytic files to identify patients with aortic stenosis and a recent hospitalization for
more » ... heart failure, who did not undergo valve replacement surgery within the ensuing 2 calendar quarters. These patients (n=2150) were considered to have medically managed severe aortic stenosis and were tracked over 5 years to measure clinical outcomes, medical resource use, and costs (from the perspective of the Medicare Program). The mean age of the cohort was 82 years, 64% were female, and the estimated logistic European System for Cardiac Operative Risk Evaluation (EuroSCORE) (a measure of predicted mortality with cardiac surgery) was 17%. During 5 years of follow-up, overall mortality was 88.4% with a mean survival duration of 1.8 years. During this time period, patients experienced an average of 4.4 hospital admissions, 52% were admitted to skilled nursing care, and 28% were admitted to hospice care. The total 5-year costs were $63 844 per patient, whereas mean annual follow-up costs (excluding the index quarter) per year alive were $29 278. Conclusions-Elderly patients with severe aortic stenosis undergoing medical management have limited long-term survival and incur substantial costs to the Medicare Program. These results have important implications for policy makers interested in better understanding the cost-effectiveness of emerging treatment options such as transcatheter aortic valve replacement. (Circ Cardiovasc Qual Outcomes. 2012;5:697-704.)
doi:10.1161/circoutcomes.112.966002 pmid:22949492 fatcat:jqbu7rc5vfgu7jy6srf2e7wkgq